GREENVILLE, S.C., March 29 /PRNewswire-FirstCall/ -- Signalife, Inc. , a medical device company focused on the detection of cardiovascular disease through continuous ECG monitoring, announced today that the company was awarded the Frost & Sullivan 2006 Technology Innovation Award in the field of ECG Monitoring.
Signalife’s signal processing technology is the heart of their ECG system, the Fidelity 100. Originally developed to read brain waves of US Air Force F-16 pilots to objectively determine their performance, Signalife’s technology is focused on signal fidelity. The FDA approved Fidelity 100, allows for the recording of a high-quality ECG signal from cardiac patients who are moving.
Frost & Sullivan’s Technology Innovation Award is bestowed upon companies that have carried out new research, which has resulted in innovations that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The Award recognizes the quality and depth of a company’s research and development as well as the vision and risk-taking that enabled it to undertake such an endeavor. Other recipients for this award include IBM, Philips and Honeywell to name a few.
Pamela Bunes, President and CEO of Signalife, states, “We are very proud to be recognized by Frost & Sullivan for our technology. This Award validates the significance of our amplification and signal processing technology. We are honored to be recognized as innovators in the field of electrocardiography. Our technology will be used in the future for early detection of other disease states as well.”
Sachin Thukral, Senior Research Analyst, of Frost & Sullivan, states, “Each year, Frost & Sullivan honors companies that demonstrate excellence in technological innovation. Signalife has demonstrated a compelling breakthrough in signal processing technology that could give new direction to ECG monitoring.”
About Signalife
Signalife, Inc. is a medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring. The company’s goal is to become the premier provider of cardiovascular disease monitoring products. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory environment. Signalife’s revolutionary FDA-approved electrocardiograph (ECG) monitoring system called Fidelity 100 allows for the recording of a quality ECG signal from ambulatory cardiac patients. The Fidelity 100 will address a portion of the $400 billion cardiac disease market. Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. The company’s website is available at: http://www.signalife.com .
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com .
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward-looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife, Inc. results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approval governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Signalife’s products or services, adverse equity market conditions and declines in the value of Signalife’s common stock, and the unavailability of financing to complete management’s plans and objectives. These risks are qualified by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.
Signalife, Inc.
CONTACT: Media: Adam J. Handelsman, SVP & GM of 5W Public Relations, x202,ahandelsman@5wpr.com, or Investor Relations: Mark Cohen, Vice President of5W Public Relations IR, x244, mcohen@5wpr.com, both for Signalife, Inc.,+1-212-999-5585; or Corporate Communications: Claire Mouton LaFrance,Director of Marketing & Communications of Signalife +1-864-233-2300,clafrance@signalife.com